Physician profile
Eric A Kelts
NPI 1861541005
$3,003.23
in general payments reported to CMS, 2019-2025
34 companies · $583 in 2025
The $583 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $283 · 2021: $669 · 2022: $683 · 2023: $172 · 2024: $74.78 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $296.80 | 2021-2025 | Ultomiris |
| Biogen, INC. | $284.01 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $258.38 | 2019-2022 | |
| Abbvie INC. | $249.94 | 2022-2025 | |
| Allergan, INC. | $171.89 | 2019-2020 | |
| Pfizer INC. | $157.08 | 2019-2025 | |
| Emd Serono, INC. | $139.28 | 2025 | Mavenclad |
| Genentech USA, INC. | $132.81 | 2021-2022 | |
| Tg Therapeutics, INC. | $128.05 | 2025 | |
| Jazz Pharmaceuticals INC. | $125.01 | 2025 | |
| Amgen INC. | $123.78 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $113.39 | 2020-2022 | |
| Ucb, INC. | $110.10 | 2019-2021 | |
| Celgene Corporation | $96.48 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $89.49 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $75.57 | 2019 | |
| Csl Behring | $48.21 | 2021-2022 | |
| Livanova USA, INC. | $48.15 | 2019 | |
| Acadia Pharmaceuticals INC | $45.00 | 2020-2022 | |
| Harmony Biosciences LLC | $38.98 | 2021 | |
| Genzyme Corporation | $35.48 | 2019 | |
| Kyowa Kirin, INC. | $29.05 | 2021 | |
| Sk Life Science, INC. | $28.47 | 2021-2022 | |
| Argenx US, INC. | $27.50 | 2022 | |
| Grt US Holding, INC. | $19.27 | 2022 | |
| Aquestive Therapeutics, INC. | $17.58 | 2020 | |
| Greenwich Biosciences, INC. | $16.40 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.63 | 2021 | |
| Upsher-Smith Laboratories LLC | $15.61 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.51 | 2022 | |
| Tanabe Pharma America, INC. | $14.24 | 2021 | |
| Zogenix INC. | $13.42 | 2021 | |
| Neurocrine Biosciences, INC. | $11.90 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Kelts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.